3.08
+0.07
(2.33%)
After Hours: 3.03
-0.05
(-1.62%)
May 21, 6:58PM EDT
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 2.94 - 3.11 |
| 52 week | 2.34 - 5.86 |
| Open | 3.05 |
| Vol / Avg. | 339,283.00/549,189.00 |
| Mkt cap | 139.62M |
| P/E | - |
| Div/yield | 0.75 |
| EPS | -0.10 |
| Shares | 45.33M |
| Beta | 0.56 |
| Inst. own | 65% |
Events
Jul 29, 2013
Q2 2013 Pain Therapeutics, Inc. Earnings Release
May 14, 2013
Pain Therapeutics, Inc. at Bank of America Merrill Lynch Health Care Conference
May 6, 2013
Q1 2013 Pain Therapeutics, Inc. Earnings Release
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -20.84% | -31.64% |
| Operating margin | -22.63% | -35.79% |
| EBITD margin | - | -34.66% |
| Return on average assets | -2.93% | -4.42% |
| Return on average equity | -12.33% | -11.98% |
| Employees | 10 | - |
| Carbon Disclosure Rating | - | - |
Address
Suite 260 7801 N Capital of Texas Highway
AUSTIN, TX 78731
United States - Map
+1-512-5012444 (Phone)
+1-512-6140414 (Fax)
AUSTIN, TX 78731
United States - Map
+1-512-5012444 (Phone)
+1-512-6140414 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Pain Therapeutics, Inc. is a biopharmaceutical company that develops drugs. The Company has four drug candidates in clinical programs, including REMOXY, abuse-resistant hydromorphone, abuse-resistant hydrocodone and a radio-labeled monoclonal antibody to treat metastatic melanoma. It is also working on a new treatment for patients with hemophilia. It has collaboration agreement with King Pharmaceuticals, Inc. (King) develops and commercializes REMOXY and other opioid painkillers. The Company and King jointly managed a Phase III clinical program and New Drug Application (NDA) submission for REMOXY. It is also developing a pipeline of drug candidates in the area of oncology and hematology. It owns all commercial rights to its pipeline of drug candidates in oncology and hematology. As of December 31, 2010, it leased approximately 30,700 square feet of space in San Mateo, California and all of its operations are located in San Mateo.
Officers and directors
| Remi Barbier | Chairman of the Board, President, Chief Executive Officer | |
| Nadav Friedmann M.D., Ph.D. | Chief Medical and Operating Officer, Director | |
| Peter S. Roddy | Chief Financial Officer, Vice President | |
| Grant L. Schoenhard Ph.D. | Chief Scientific Officer | |
| Michael J. O' Donnell Esq. | Secretary, Independent Director | |
| Robert Z. Gussin Ph.D. | Independent Director | |
| Saira Ramasastry | Independent Director | |
| Sanford R. Robertson | Independent Director | |
| Patrick J. Scannon M.D., Ph.D. | Independent Director |
